Acute multifocal CNS demyelination as first presentation of systemic malignancy

Neurology ◽  
2005 ◽  
Vol 65 (1) ◽  
pp. 166-166 ◽  
Author(s):  
N. Gonzales ◽  
E. Jarboe ◽  
B. K. Kleinschmidt-DeMasters ◽  
P. Bosque
Keyword(s):  
Cns Demyelination ◽  
Systemic Malignancy

scholarly journals CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant

2021 ◽  
pp. 135245852096389
Author(s):  
Stefania Kaninia ◽  
Alexandros Grammatikos ◽  
Kathryn Urankar ◽  
Shelley A Renowden ◽  
Nikunj K Patel ◽  
...  
Keyword(s):  
T Cell Activation ◽  
Cell Activation ◽  
Cytotoxic T Lymphocyte ◽  
Checkpoint Inhibitors ◽  
Novel Treatments ◽  
First Case ◽  
Self Tolerance ◽  
Autoimmune Conditions ◽  
History Of ◽  
Cns Demyelination

Background: The cytotoxic T-lymphocyte antigen-4 (CTLA-4) pathway acts as a negative immune regulator of T-cell activation and promotes self-tolerance. Case: We report the first case of biopsy-proven central nervous system inflammatory demyelination in the context of primary immunodeficiency and a novel CTLA-4 variant. Conclusion: This case has significant implications for the development of novel treatments for autoimmune conditions including multiple sclerosis and further emphasises the need for caution with clinical use of CTLA-4 immune checkpoint inhibitors in those with a history of inflammatory demyelination.

scholarly journals Protocol for a mouse CNS demyelination model induced by a combination of HSV-1 and IL-2

2021 ◽  
Vol 2 (1) ◽  
pp. 100287
Author(s):  
Satoshi Hirose ◽  
Kati Tormanen ◽  
Mihoko Kato ◽  
Jack Yu ◽  
Homayon Ghiasi
Keyword(s):  
Cns Demyelination ◽  
Hsv 1

Osteopontin is extensively expressed by macrophages following CNS demyelination but has a redundant role in remyelination

2008 ◽  
Vol 31 (2) ◽  
pp. 209-217 ◽  
Author(s):  
Chao Zhao ◽  
Stephen P.J. Fancy ◽  
Charles ffrench-Constant ◽  
Robin J.M. Franklin
Keyword(s):  
Cns Demyelination ◽  
Redundant Role

Diagnostic challenges in neoplastic meningitis presenting as intracranial hypertension

2021 ◽  
Vol 14 (3) ◽  
pp. e238808
Author(s):  
Santosh Sriram Andugulapati ◽  
Akash Chheda ◽  
Karan Desai ◽  
Sangeeta Hasmukh Ravat
Keyword(s):  
Cerebrospinal Fluid ◽  
Intracranial Hypertension ◽  
Neoplastic Meningitis ◽  
Whole Body ◽  
Csf Cytology ◽  
Csf Analysis ◽  
Pet Ct ◽  
Pet Ct Scan ◽  
Systemic Malignancy

A diagnosis of idiopathic intracranial hypertension should be considered only after careful exclusion of all possible aetiologies. We report a case of neoplastic meningitis presenting as intracranial hypertension with inconclusive repeated cerebrospinal fluid (CSF) cytology and MRI of brain, emphasising the importance of meticulous CSF analysis and role of early whole-body PET–CT scan for diagnosis of systemic malignancy.

RELAPSING-REMITTING EAE IN THE MOUSEI CNS DEMYELINATION AND REMYELINATION

1985 ◽  
Vol 44 (3) ◽  
pp. 318
Author(s):  
F. D. Lublln ◽  
R. L. Knobler ◽  
S. Duckett ◽  
W. G. Beamer
Keyword(s):  
Relapsing Remitting ◽  
Cns Demyelination

scholarly journals Accelerated Axonal Loss Following Acute CNS Demyelination in Mice Lacking Protein Tyrosine Phosphatase Receptor Type Z

2012 ◽  
Vol 181 (5) ◽  
pp. 1518-1523 ◽  
Author(s):  
Jeffrey K. Huang ◽  
Carina C. Ferrari ◽  
Glaucia Monteiro de Castro ◽  
David Lafont ◽  
Chao Zhao ◽  
...  
Keyword(s):  
Protein Tyrosine Phosphatase ◽  
Tyrosine Phosphatase ◽  
Receptor Type ◽  
Axonal Loss ◽  
Protein Tyrosine ◽  
Cns Demyelination

scholarly journals Pathological findings in central nervous system demyelination associated with infliximab

2019 ◽  
Vol 26 (9) ◽  
pp. 1124-1129 ◽  
Author(s):  
Alicja Kalinowska-Lyszczarz ◽  
Mahboobeh Fereidan-Esfahani ◽  
Yong Guo ◽  
Claudia F Lucchinetti ◽  
W Oliver Tobin
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Tnf Alpha ◽  
Infliximab Treatment ◽  
Necrosis Factor Alpha ◽  
Immune Mediated ◽  
Central Nervous System Demyelination ◽  
Factor Alpha ◽  
Cns Demyelination ◽  
Necrosis Factor

Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). Methods: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. Results and conclusion: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.

Sign in / Sign up

Export Citation Format

Share Document